BRIEF-Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc

Reuters
02 Jun
BRIEF-Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc

June 2 (Reuters) - Zai Lab Ltd 9688.HK:

  • ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATING ROBUST ANTI-TUMOR ACTIVITY AND SAFETY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER AT 2025 ASCO ANNUAL MEETING

Source text: ID:nBwzHvjLa

Further company coverage: 9688.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10